S
Steven D. Nathan
Researcher at Inova Fairfax Hospital
Publications - 355
Citations - 14679
Steven D. Nathan is an academic researcher from Inova Fairfax Hospital. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Pulmonary hypertension. The author has an hindex of 51, co-authored 296 publications receiving 11856 citations.
Papers
More filters
Journal ArticleDOI
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Talmadge E. King,Williamson Z. Bradford,Socorro Castro-Bernardini,Elizabeth A. Fagan,Ian Glaspole,Marilyn K. Glassberg,Eduard Gorina,Peter Hopkins,David Kardatzke,Lisa Lancaster,David J. Lederer,Steven D. Nathan,Carlos Alberto de Castro Pereira,Steven A. Sahn,Robert Sussman,Jeffrey J. Swigris,Paul W. Noble +16 more
TL;DR: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis.
Journal ArticleDOI
International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation.
Jonathan B. Orens,Marc Estenne,Selim M. Arcasoy,John V. Conte,Paul A. Corris,Jim J. Egan,Thomas M. Egan,Shaf Keshavjee,Christiane Knoop,Robert M. Kotloff,Fernando J. Martinez,Steven D. Nathan,Scott M. Palmer,A. Patterson,Lianne G. Singer,Gregory I Snell,Sean M. Studer,Jean-Luc Vachiery,Allan R. Glanville +18 more
TL;DR: This update to the international guidelines is based primarily on a consensus of opinion rendered by experts in the field and should not be considered to be hard and fast rules.
Journal ArticleDOI
Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis
TL;DR: PAH is common in advanced cases of IPF and significantly impacts survival and might be an important adjunct in monitoring disease progression, triaging for transplantation, and guiding therapy.
Journal ArticleDOI
Pulmonary hypertension in chronic lung disease and hypoxia.
Steven D. Nathan,Joan Albert Barberà,Sean Gaine,Sergio Harari,Fernando J. Martinez,Horst Olschewski,Karen M. Olsson,Andrew J. Peacock,Joanna Pepke-Zaba,Steeve Provencher,Norbert Weissmann,Werner Seeger +11 more
TL;DR: Who, when, if and how to screen for PH will be addressed, as will the current state of knowledge with regard to the role of treatment with pulmonary vasoactive agents.
Journal ArticleDOI
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
Paul W. Noble,Carlo Albera,Williamson Z. Bradford,Ulrich Costabel,Roland M. du Bois,Elizabeth A. Fagan,Robert S. Fishman,Ian Glaspole,Marilyn K. Glassberg,Lisa Lancaster,David J. Lederer,Jonathan A. Leff,Steven D. Nathan,Carlos Alberto de Castro Pereira,Jeffrey J. Swigris,Dominique Valeyre,Talmadge E. King +16 more
TL;DR: Analysis of data from three phase 3 trials demonstrated that treatment with pirfenidone for 1 year resulted in clinically meaningful reductions in disease progression in patients with IPF.